Cytokinetics

Cytokinetics to Participate in March Investor Conferences

Retrieved on: 
Monday, March 4, 2024

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March:
    Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, Andrew Callos, Executive Vice President and Chief Commercial Officer, and Fady I. Malik, Executive Vice President of Research & Development, will participate in a fireside chat on Monday, March 11, 2024 at 1:20 PM Eastern Time at the Fontainebleau Miami Beach Hotel in Miami Beach, FL.
  • Jefferies Biotech on the Bay Summit: Management will participate in one-on-one meetings on Tuesday, March 12, 2024 at the W South Beach Hotel in Miami Beach, FL.
  • Interested parties may access the live webcasts of the fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com .
  • The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 1, 2024

SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment.
  • The stock options that were granted are subject to an exercise price of $72.24 per share, which is equal to the closing price of the Company’s common stock on February 29, 2024, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the subsequent 36 months, subject to the new employee’s continued service with the Company.
  • Each stock option has a 10-year term and is subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®.
  • Rare Disease Day® is an international campaign elevating the awareness and public understanding of rare diseases.
  • The initiative spotlights the more than 300 million people worldwide living with a rare disease, and the awareness efforts focused on bringing them more equitable access to diagnosis, treatment, care and social opportunity.
  • “We are proud to be joining EURORDIS, NORD and countless others worldwide to recognize Rare Disease Day and stand in support of those who bravely navigate the complexities and challenges of rare diseases," said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

Retrieved on: 
Wednesday, February 28, 2024

ENACT is a joint initiative of The Mended Hearts, Inc. and WomenHeart, made possible through grant funding from Cytokinetics provided to each organization to address their respective constituencies.

Key Points: 
  • ENACT is a joint initiative of The Mended Hearts, Inc. and WomenHeart, made possible through grant funding from Cytokinetics provided to each organization to address their respective constituencies.
  • The goal of ENACT is to provide greater education to patients with cardiovascular diseases participating in clinical trials.
  • During the initial launch, The Mended Hearts, Inc. and WomenHeart will create complementary content, modules and resources based on their unique expertise and constituencies.
  • “We commend The Mended Hearts, Inc. and WomenHeart on this joint initiative to help make cardiovascular clinical trials more accessible, approachable and inclusive,” said Mary Pomerantz, Cytokinetics’ Senior Director of Patient Advocacy and Engagement.

Cytokinetics Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2023. Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 million or $5.45 per share. Net loss for the fourth quarter of 2022 was $137.4 million or $1.45 per share and net loss for the year 2022 was $389.0 million or $4.33 per share. Cash, cash equivalents and investments totaled $655.4 million on December 31, 2023. This cash balance does not include approximately $83 million in net proceeds generated in early 2024 from the sale of common stock through an at-the-market equity vehicle.

Key Points: 
  • Company Provides 2024 Financial Guidance; Approximately 2 Years of Cash Runway
    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the fourth quarter and full year 2023.
  • Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 million or $5.45 per share.
  • “We ended 2023 strong with positive results from SEQUOIA-HCM which now propel our company forward to the next stages of planning towards our specialty cardiology business model,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.
  • Members of Cytokinetics’ senior management team will review the company’s fourth quarter 2023 results on a conference call today at 4:30 PM Eastern Time.

Royalty Pharma Reports Q4 and Full Year 2023 Results

Retrieved on: 
Thursday, February 15, 2024

In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.

Key Points: 
  • In October 2023, Royalty Pharma drew $350 million under its existing unsecured revolving credit facility, which was repaid during the fourth quarter of 2023.
  • Royalty Pharma began repurchasing its Class A ordinary shares in April 2023 under a $1.0 billion multi-year share repurchase program.
  • During the fourth quarter of 2023, Royalty Pharma announced new transactions of up to $1.6 billion.
  • Royalty Pharma will host a conference call and simultaneous webcast to discuss its fourth quarter and full year 2023 results today at 8:00 a.m., Eastern Time.

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

Retrieved on: 
Tuesday, February 13, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time.
  • Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.
  • The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com .
  • An archived replay of the webcast will be available via Cytokinetics’ website for twelve months.

Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time.
  • Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com .
  • The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program

Retrieved on: 
Monday, January 29, 2024

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement.
  • The grants will support projects to increase access to resources, grow organizational reach and launch educational programs.
  • Cardiomyopathy UK will use the grant to expand Reaching Further, a project aimed at educating those not diagnosed with cardiomyopathy about the symptoms and warning signs.
  • The grant will allow Cardiomyopathy UK to create 15 additional case study stories and refine and optimize the organization’s website.

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

Retrieved on: 
Thursday, January 25, 2024

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension clinical trial of aficamten in patients with hypertrophic cardiomyopathy (HCM).
  • At the time of this analysis, 16 patients in FOREST-HCM had completed a CMR at baseline and at Week 48.
  • Baseline characteristics of the CMR cohort were comparable to the overall patient population in FOREST-HCM.
  • We look forward to expanding on these data in the future.”